MA51889A - Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes - Google Patents
Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytesInfo
- Publication number
- MA51889A MA51889A MA051889A MA51889A MA51889A MA 51889 A MA51889 A MA 51889A MA 051889 A MA051889 A MA 051889A MA 51889 A MA51889 A MA 51889A MA 51889 A MA51889 A MA 51889A
- Authority
- MA
- Morocco
- Prior art keywords
- reduce
- protein inhibitors
- hepatocyte death
- hepatic regeneration
- promote hepatic
- Prior art date
Links
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 title 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 title 1
- 230000002440 hepatic effect Effects 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154454 | 2018-01-31 | ||
| EP18183692 | 2018-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51889A true MA51889A (fr) | 2021-05-05 |
Family
ID=65228576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051889A MA51889A (fr) | 2018-01-31 | 2019-01-30 | Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11858927B2 (fr) |
| EP (1) | EP3746437B1 (fr) |
| JP (1) | JP7337813B2 (fr) |
| KR (1) | KR102834253B1 (fr) |
| CN (1) | CN111788195B (fr) |
| AU (1) | AU2019216264B2 (fr) |
| BR (1) | BR112020015072A2 (fr) |
| CA (1) | CA3089678A1 (fr) |
| DK (1) | DK3746437T3 (fr) |
| ES (1) | ES3000465T3 (fr) |
| FI (1) | FI3746437T3 (fr) |
| HR (1) | HRP20241555T1 (fr) |
| HU (1) | HUE069545T2 (fr) |
| IL (1) | IL276353B2 (fr) |
| MA (1) | MA51889A (fr) |
| MX (1) | MX2020007954A (fr) |
| PL (1) | PL3746437T3 (fr) |
| SG (1) | SG11202007143UA (fr) |
| WO (1) | WO2019149738A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019149738A1 (fr) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3104246A1 (fr) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Inhibiteurs de proteine kinase permettant de favoriser la regeneration du foie, ou de reduire ou de prevenir la mort des hepatocytes |
| CN114269745B (zh) * | 2019-07-29 | 2025-04-22 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或减少或预防肝细胞死亡的杂芳基取代的吡唑并吡啶蛋白激酶抑制剂 |
| ES2984974T3 (es) | 2020-01-15 | 2024-10-31 | Heparegenix Gmbh | Derivados de 3-benzoil-1H-pirrolo[2,3-b]piridina como inhibidores de MKK4 para el tratamiento de hepatopatías |
| CN111423443A (zh) * | 2020-04-03 | 2020-07-17 | 广州科锐特生物科技有限公司 | 一种4-氨基-7-碘吡咯并[2,1-f][1,2,4]三嗪的制备方法 |
| WO2021249913A1 (fr) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer |
| JP2023536814A (ja) * | 2020-07-30 | 2023-08-30 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 細胞の増殖を刺激する方法 |
| CN112194661B (zh) * | 2020-10-22 | 2021-06-08 | 威海同丰海洋生物科技有限公司 | 一种4-氨基-7-碘吡咯并[2,l-f][l,2,4]三嗪的制备方法 |
| US20240174683A1 (en) | 2021-02-05 | 2024-05-30 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| US20250228834A1 (en) | 2022-04-06 | 2025-07-17 | Heparegenix Gmbh | Pharmaceutical composition for the treatment of colon and lung cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
| US7129225B2 (en) | 2001-10-22 | 2006-10-31 | The Research Foundation Of State University Of New York | Protection against and treatment of hearing loss |
| WO2003037898A1 (fr) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Derives de pyrimido [4,5-b] indole |
| AU2003300522A1 (en) | 2002-12-27 | 2004-07-22 | Bayer Healthcare Ag | 4-phenyl-pyrimido (4,5-b) indole derivatives |
| FR2876377B1 (fr) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
| JP2006282745A (ja) | 2005-03-31 | 2006-10-19 | Fuji Photo Film Co Ltd | セルロース誘導体組成物、セルロース誘導体フィルム、および置換安息香酸誘導体化合物 |
| KR20080027775A (ko) | 2005-05-17 | 2008-03-28 | 플렉시콘, 인코퍼레이티드 | 피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제 |
| PL1893612T3 (pl) | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| WO2008063888A2 (fr) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées |
| PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| EP2161271A1 (fr) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Inhibiteurs d'alpha-carboline de NMP-ALK, RET, et Bcr-Abl |
| WO2010104945A1 (fr) | 2009-03-11 | 2010-09-16 | Plexxikon, Inc. | Dérivés de pyrrolo [2, 3-b] pyridine pour l'inhibition des kinases raf |
| WO2010111527A1 (fr) * | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2947073B1 (fr) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Analogues cycliques fusionnés d'agents antifibrotiques |
| WO2011079133A2 (fr) | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Composés et méthodes pour la modulation des kinases, et leurs indications |
| CN103517710B (zh) | 2011-02-07 | 2017-05-31 | 普莱希科公司 | 用于激酶调节的化合物 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| WO2012135631A1 (fr) | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | 5-(pyrazin-2-yl)-1h-pyrazolo[3,4-b]pyridine substituée et dérivés de pyrazolo[3,4-b]pyridine en tant qu'inhibiteurs de protéine kinase |
| EP2508607A1 (fr) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| JP6002223B2 (ja) | 2011-08-26 | 2016-10-05 | ニューファーマ， インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| US9688635B2 (en) | 2012-09-24 | 2017-06-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| RU2015149937A (ru) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
| BR112017014341A2 (pt) | 2015-01-09 | 2018-03-27 | Gilead Apollo, Llc | método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição. |
| WO2017066193A1 (fr) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Nouveaux inhibiteurs de protéines kinases |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| MX2020001531A (es) | 2017-08-07 | 2020-03-20 | Biocad Joint Stock Co | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. |
| WO2019149738A1 (fr) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes |
| RU2678455C1 (ru) * | 2018-06-01 | 2019-01-29 | Сергей Викторович Леонов | Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3104246A1 (fr) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Inhibiteurs de proteine kinase permettant de favoriser la regeneration du foie, ou de reduire ou de prevenir la mort des hepatocytes |
| EP3847159A2 (fr) | 2018-09-04 | 2021-07-14 | Magenta Therapeutics, Inc. | Antagonistes du récepteur de l'aryl-hydrocarbone et procédés d'utilisation de ces derniers |
| US12098117B2 (en) | 2018-12-11 | 2024-09-24 | Duke University | Compositions and methods for the treatment of cancer |
| US11370770B2 (en) | 2019-06-24 | 2022-06-28 | Northwestern University | 3-arylindazoles as selective MEK4 inhibitors |
| CN114269745B (zh) | 2019-07-29 | 2025-04-22 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或减少或预防肝细胞死亡的杂芳基取代的吡唑并吡啶蛋白激酶抑制剂 |
| CN112778311B (zh) | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
| ES2984974T3 (es) | 2020-01-15 | 2024-10-31 | Heparegenix Gmbh | Derivados de 3-benzoil-1H-pirrolo[2,3-b]piridina como inhibidores de MKK4 para el tratamiento de hepatopatías |
| WO2022150962A1 (fr) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Inhibiteurs de protéase, leur préparation et leurs utilisations |
-
2019
- 2019-01-30 WO PCT/EP2019/052213 patent/WO2019149738A1/fr not_active Ceased
- 2019-01-30 AU AU2019216264A patent/AU2019216264B2/en active Active
- 2019-01-30 ES ES19701674T patent/ES3000465T3/es active Active
- 2019-01-30 PL PL19701674.4T patent/PL3746437T3/pl unknown
- 2019-01-30 MX MX2020007954A patent/MX2020007954A/es unknown
- 2019-01-30 KR KR1020207021909A patent/KR102834253B1/ko active Active
- 2019-01-30 BR BR112020015072-0A patent/BR112020015072A2/pt unknown
- 2019-01-30 HU HUE19701674A patent/HUE069545T2/hu unknown
- 2019-01-30 US US16/965,912 patent/US11858927B2/en active Active
- 2019-01-30 DK DK19701674.4T patent/DK3746437T3/da active
- 2019-01-30 IL IL276353A patent/IL276353B2/en unknown
- 2019-01-30 JP JP2020540553A patent/JP7337813B2/ja active Active
- 2019-01-30 HR HRP20241555TT patent/HRP20241555T1/hr unknown
- 2019-01-30 CA CA3089678A patent/CA3089678A1/fr active Pending
- 2019-01-30 CN CN201980011310.4A patent/CN111788195B/zh active Active
- 2019-01-30 SG SG11202007143UA patent/SG11202007143UA/en unknown
- 2019-01-30 FI FIEP19701674.4T patent/FI3746437T3/fi active
- 2019-01-30 EP EP19701674.4A patent/EP3746437B1/fr active Active
- 2019-01-30 MA MA051889A patent/MA51889A/fr unknown
-
2023
- 2023-11-08 US US18/388,084 patent/US12264158B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12264158B2 (en) | 2025-04-01 |
| JP2021514346A (ja) | 2021-06-10 |
| KR102834253B1 (ko) | 2025-07-15 |
| RU2020125133A3 (fr) | 2022-02-28 |
| PL3746437T3 (pl) | 2025-01-07 |
| US20210078995A1 (en) | 2021-03-18 |
| DK3746437T3 (da) | 2024-11-11 |
| RU2020125133A (ru) | 2022-02-28 |
| EP3746437B1 (fr) | 2024-08-21 |
| HUE069545T2 (hu) | 2025-03-28 |
| US20240116931A1 (en) | 2024-04-11 |
| US11858927B2 (en) | 2024-01-02 |
| SG11202007143UA (en) | 2020-08-28 |
| ES3000465T3 (en) | 2025-02-28 |
| CN111788195B (zh) | 2023-11-21 |
| KR20200138166A (ko) | 2020-12-09 |
| CN111788195A (zh) | 2020-10-16 |
| AU2019216264A1 (en) | 2020-08-13 |
| CA3089678A1 (fr) | 2019-08-08 |
| HRP20241555T1 (hr) | 2025-01-17 |
| FI3746437T3 (fi) | 2024-11-21 |
| JP7337813B2 (ja) | 2023-09-04 |
| BR112020015072A2 (pt) | 2021-01-05 |
| IL276353B2 (en) | 2024-02-01 |
| AU2019216264B2 (en) | 2023-08-31 |
| IL276353B1 (en) | 2023-10-01 |
| EP3746437A1 (fr) | 2020-12-09 |
| IL276353A (en) | 2020-09-30 |
| MX2020007954A (es) | 2021-01-08 |
| WO2019149738A1 (fr) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51889A (fr) | Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes | |
| HUE062404T2 (hu) | Protein tirozin foszfatáz inhibitorok | |
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| EP3762414A4 (fr) | Dosages pour détecter la neurodégénérescence | |
| IL279641A (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocytic death | |
| ZA201905078B (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| MA71266A (fr) | Procédés d'intervention précoce pour prévenir ou améliorer la toxicité | |
| EP3761992A4 (fr) | Inhibiteurs d'arginase | |
| EP3455218A4 (fr) | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles | |
| EP3890733A4 (fr) | Inhibiteurs de protéine kinase activés par le mitogène p38 de site non atp/catalytique | |
| EP3334430A4 (fr) | Atropisomérisme pour une sélectivité accrue des inhibiteurs de kinase | |
| MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
| EP3458420A4 (fr) | Espaceur antibiofilm et antimicrobien pour membrane fonctionnelle | |
| DK3381451T3 (da) | Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning | |
| IL290190B2 (en) | Pyrazolopyridine-substituted heteroaryl protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| MA43587A (fr) | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 | |
| EP3810178A4 (fr) | Polypeptides cycliques pour l'inhibition de la pcsk9 | |
| EP3365403A4 (fr) | Combinaison d'inhibiteurs de cobalt pour un bombage amélioré | |
| EP3810176A4 (fr) | Polypeptides cycliques pour l'inhibition de la pcsk9 | |
| EP3942972A4 (fr) | Cintre pour vêtement | |
| EP3555092A4 (fr) | Inhibiteurs de protéine kinase | |
| EP3883950A4 (fr) | Protéines pour bloquer la libération de neurotransmetteurs | |
| EP3305291A4 (fr) | Utilisation de dérivé de benzimidazole pour l'acidité nocturne | |
| FR3050174B1 (fr) | Combinaison pour activite aquatique | |
| EP3378491A4 (fr) | Composition pharmaceutique pour traiter ou prévenir la stéatohépatite non alcoolique (nash) |